[HTML][HTML] Antidiabetic agents as a novel treatment for Alzheimer's and Parkinson's disease
J Nowell, E Blunt, D Gupta, P Edison - Ageing Research Reviews, 2023 - Elsevier
Therapeutic strategies for neurodegenerative disorders have commonly targeted individual
aspects of the disease pathogenesis to little success. Neurodegenerative diseases …
aspects of the disease pathogenesis to little success. Neurodegenerative diseases …
Dissociable hindbrain GLP1R circuits for satiety and aversion
KP Huang, AA Acosta, MY Ghidewon, AD McKnight… - Nature, 2024 - nature.com
The most successful obesity therapeutics, glucagon-like peptide-1 receptor (GLP1R)
agonists, cause aversive responses such as nausea and vomiting,, effects that may …
agonists, cause aversive responses such as nausea and vomiting,, effects that may …
[HTML][HTML] The gut–brain axis: Identifying new therapeutic approaches for type 2 diabetes, obesity, and related disorders
P Richards, NA Thornberry, S Pinto - Molecular Metabolism, 2021 - Elsevier
Background The gut-brain axis, which mediates the bi-directional communication between
the gastrointestinal system and the central nervous system (CNS), plays a fundamental role …
the gastrointestinal system and the central nervous system (CNS), plays a fundamental role …
[HTML][HTML] Anorectic and aversive effects of GLP-1 receptor agonism are mediated by brainstem cholecystokinin neurons, and modulated by GIP receptor activation
A Costa, M Ai, N Nunn, I Culotta, J Hunter… - Molecular …, 2022 - Elsevier
Objective Glucagon-like peptide-1 receptor agonists (GLP-1RAs) are effective medications
to reduce appetite and body weight. These actions are centrally mediated; however, the …
to reduce appetite and body weight. These actions are centrally mediated; however, the …
[HTML][HTML] Whole-brain activation signatures of weight-lowering drugs
HH Hansen, J Perens, U Roostalu, JL Skytte… - Molecular …, 2021 - Elsevier
Objective The development of effective anti-obesity therapeutics relies heavily on the ability
to target specific brain homeostatic and hedonic mechanisms controlling body weight. To …
to target specific brain homeostatic and hedonic mechanisms controlling body weight. To …
Use of a biomimetic hydrogel depot technology for sustained delivery of GLP-1 receptor agonists reduces burden of diabetes management
Summary Glucagon-like peptide-1 (GLP-1) is an incretin hormone and neurotransmitter
secreted from intestinal L cells in response to nutrients to stimulate insulin and block …
secreted from intestinal L cells in response to nutrients to stimulate insulin and block …
Distribution and ultrastructural localization of the glucagon-like peptide-1 receptor (GLP-1R) in the rat brain
E Farkas, A Szilvásy-Szabó, Y Ruska, R Sinkó… - Brain Structure and …, 2021 - Springer
Abstract Glucagon-like peptide-1 (GLP-1) inhibits food intake and regulates glucose
homeostasis. These actions are at least partly mediated by central GLP-1 receptor (GLP …
homeostasis. These actions are at least partly mediated by central GLP-1 receptor (GLP …
Semaglutide as a promising treatment for hypothalamic obesity: a six-month case series on four females with craniopharyngioma
E Gjersdal, LB Larsen, KS Ettrup, P Vestergaard… - Pituitary, 2024 - Springer
Purpose Patients with hypothalamic pathology often develop hypothalamic obesity, causing
severe metabolic alterations resulting in increased morbidity and mortality. Treatments for …
severe metabolic alterations resulting in increased morbidity and mortality. Treatments for …
Anorexigenic and anti-inflammatory signaling pathways of semaglutide via the microbiota–gut––brain axis in obese mice
RS da Silva, IHR de Paiva, IP Mendonça… - …, 2024 - Springer
Our study focused on a mouse model of obesity induced by a high-fat diet (HFD). We
administered Semaglutide intraperitoneally (Ozempic®—0.05 mg/Kg—translational dose) …
administered Semaglutide intraperitoneally (Ozempic®—0.05 mg/Kg—translational dose) …
Multimodal 3D Mouse Brain Atlas Framework with the Skull-Derived Coordinate System
J Perens, CG Salinas, U Roostalu, JL Skytte… - Neuroinformatics, 2023 - Springer
Magnetic resonance imaging (MRI) and light-sheet fluorescence microscopy (LSFM) are
technologies that enable non-disruptive 3-dimensional imaging of whole mouse brains. A …
technologies that enable non-disruptive 3-dimensional imaging of whole mouse brains. A …